Patients with chronic kidney disease (CKD) are known to have aggressive and complex cardiovascular disease burden and the absolute risk of death increases exponentially with the stages of CKD.1 Two major pathways in CKD that are yet to be amenable to therapeutic approaches are accelerated atherosclerosis and vascular calcification.2 In addition to the traditional cardiovascular risk factors,3 numerous CKD-related risk factors, including inflammation, oxidative stress, uremic toxins, and perturbed mineral metabolism can escalate vascular calcification pathogenesis and have been identified as predictors of poor cardiac outcomes and survival in patients with CKD.4,5